Literature DB >> 18057251

Independent and cooperative antiviral actions of beta interferon and gamma interferon against herpes simplex virus replication in primary human fibroblasts.

Tao Peng1, Jia Zhu, Yon Hwangbo, Lawrence Corey, Roger E Bumgarner.   

Abstract

Type I and type II interferons (IFNs) act in synergy to inhibit the replication of a variety of viruses, including herpes simplex virus (HSV). To understand the mechanism of this effect, we have analyzed the transcriptional profiles of primary human fibroblast cells that were first treated with IFN-beta1, IFN-gamma, or a combination of both and then subsequently infected with HSV-1. We have identified two types of synergistic activities in the gene expression patterns induced by IFN-beta1 and IFN-gamma that may contribute to inhibition of HSV-1 replication. The first is defined as "synergy by independent action," in which IFN-beta1 and IFN-gamma induce distinct gene categories. The second, "synergy by cooperative action," is a term that describes the positive interaction between IFN-beta1 and IFN-gamma as defined by a two-way analysis of variance. This form of synergy leads to a much higher level of expression for a subset of genes than is seen with either interferon alone. The cooperatively induced genes by IFN-beta1 and IFN-gamma include those involved in apoptosis, RNA degradation, and the inflammatory response. Furthermore, the combination of IFN-beta1 and IFN-gamma induces significantly more apoptosis and inhibits HSV-1 gene expression and DNA replication significantly more than treatment with either interferon alone. Taken together, these data suggest that IFN-beta1 and IFN-gamma work both independently and cooperatively to create an antiviral state that synergistically inhibits HSV-1 replication in primary human fibroblasts and that cooperatively induced apoptosis may play a role in the synergistic effect on viral replication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057251      PMCID: PMC2258722          DOI: 10.1128/JVI.01649-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Constitutive expression of (2'-5') oligo A synthetase confers resistance to picornavirus infection.

Authors:  J Chebath; P Benech; M Revel; M Vigneron
Journal:  Nature       Date:  1987 Dec 10-16       Impact factor: 49.962

Review 2.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

3.  Inhibition of VSV and EMCV replication by the interferon-induced GTPase, mGBP-2: differential requirement for wild-type GTP binding domain.

Authors:  C C Carter; V Y Gorbacheva; D J Vestal
Journal:  Arch Virol       Date:  2005-02-18       Impact factor: 2.574

4.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.

Authors:  S D Der; A Zhou; B R Williams; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus.

Authors:  S L Anderson; J M Carton; J Lou; L Xing; B Y Rubin
Journal:  Virology       Date:  1999-03-30       Impact factor: 3.616

6.  Functional genomic analysis of herpes simplex virus type 1 counteraction of the host innate response.

Authors:  Tracy Jo Pasieka; Tracey Baas; Victoria S Carter; Sean C Proll; Michael G Katze; David A Leib
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

7.  The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation.

Authors:  Tao Peng; Todd R Golub; David M Sabatini
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

8.  Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs.

Authors:  Jacek Bania; Evelina Gatti; Hugues Lelouard; Alexandre David; Fanny Cappello; Ekkehard Weber; Voahirana Camosseto; Philippe Pierre
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-14       Impact factor: 11.205

9.  Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma.

Authors:  Bruno Sainz; Heather L LaMarca; Robert F Garry; Cindy A Morris
Journal:  Virol J       Date:  2005-02-23       Impact factor: 4.099

10.  Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).

Authors:  Bruno Sainz; Eric C Mossel; C J Peters; Robert F Garry
Journal:  Virology       Date:  2004-11-10       Impact factor: 3.616

View more
  21 in total

1.  Kinetic Differences and Synergistic Antiviral Effects Between Type I and Type III Interferon Signaling Indicate Pathway Independence.

Authors:  Emily A Voigt; John Yin
Journal:  J Interferon Cytokine Res       Date:  2015-05-04       Impact factor: 2.607

2.  An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of herpes simplex virus 2 infection.

Authors:  Tao Peng; Jia Zhu; Khamsone Phasouk; David M Koelle; Anna Wald; Lawrence Corey
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

3.  Tissue-resident T cell-derived cytokines eliminate herpes simplex virus-2-infected cells.

Authors:  Pavitra Roychoudhury; David A Swan; Elizabeth Duke; Lawrence Corey; Jia Zhu; Veronica Davé; Laura Richert Spuhler; Jennifer M Lund; Martin Prlic; Joshua T Schiffer
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

4.  The interdependent, overlapping, and differential roles of type I and II IFNs in the pathogenesis of experimental autoimmune encephalomyelitis.

Authors:  Rodrigo Naves; Simer P Singh; Kevin S Cashman; Amber L Rowse; Robert C Axtell; Lawrence Steinman; John D Mountz; Chad Steele; Patrizia De Sarno; Chander Raman
Journal:  J Immunol       Date:  2013-08-19       Impact factor: 5.422

Review 5.  STAT2 and IRF9: Beyond ISGF3.

Authors:  Karin Fink; Nathalie Grandvaux
Journal:  JAKSTAT       Date:  2013-12-18

6.  The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts.

Authors:  Eric Bartee; Mohamed R Mohamed; M Cecilia Lopez; Henry V Baker; Grant McFadden
Journal:  J Virol       Date:  2008-10-29       Impact factor: 5.103

Review 7.  Cytokine synergy: an underappreciated contributor to innate anti-viral immunity.

Authors:  Eric Bartee; Grant McFadden
Journal:  Cytokine       Date:  2013-05-18       Impact factor: 3.861

8.  Evasion of the mucosal innate immune system by herpes simplex virus type 2.

Authors:  Tao Peng; Jia Zhu; Alexis Klock; Khamsone Phasouk; Meei-Li Huang; David M Koelle; Anna Wald; Lawrence Corey
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

Review 9.  Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection.

Authors:  Scott H James; David W Kimberlin; Richard J Whitley
Journal:  Antiviral Res       Date:  2009-05-04       Impact factor: 5.970

10.  Constitutive IFNα/β signaling maintains expression of signaling intermediaries for efficient cytokine responses.

Authors:  Nicole L Messina; Christopher J P Clarke; Ricky W Johnstone
Journal:  JAKSTAT       Date:  2016-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.